Abstract
In the 1940s, Charles Huggins et al. published a paper describing the clinical benefits of surgical castration and estrogen administration in prostate cancer patients. Later, Huggins was awarded the Nobel Prize to acknowledge the importance of his findings in this field. Since that time, androgen deprivation therapy (ADT) remains a standard therapy for metastatic prostate cancer. Although the main aim of ADT is the control of the serum testosterone (TST) level below the castration level, a series of evidences indicated the clinical significance of controlling the serum TST level even below the standard castration level. In terms of TST production, multiple pathways exist, such as “classical pathway” and “backdoor pathway.” Upregulation of such pathways, even inside the tumor, contributes to the acquisition of castration resistance. Thus, monitoring serum TST levels provides us further understanding of tumor behavior in individual patients. In this chapter, we will discuss the prognostic significance of monitoring serum TST levels in primary ADT for prostate cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Regis L, Iztueta I, Servian P, Kosntantinidis C, Planas J, Celma A, et al. Free serum testosterone versus total testosterone as surrogate marker for the clinical benefit of androgen suppression in prostate cancer patients. J Urol. 2014;191(4):E856-E.
Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol. 2000;163(3):824–7.
Schatzl G, Madersbacher S, Thurridl T, Waldmuller J, Kramer G, Haitel A, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001;47(1):52–8.
Neuzillet Y, Pichon A, Ghoneim T, Lebret T, Radulescu C, Molinie V, et al. High incidence of predominant gleason pattern 4 is associated with low testosterone serum level in localized prostate cancer: an update with 937 patients. J Urol. 2014;191(4):E412-E.
Isom-Batz G, Bianco FJ, Kattan MW, Mulhall JP, Lilja H, Eastham JA. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol. 2005;173(6):1935–7.
Suzuki H, Yano M, Imamoto T, Kato T, Komiya A, Naya Y, et al. Pretreatment serum testosterone level can improve the efficiency of prostate cancer screening. J. Urology. 2007;177(4):573.
Massengill JC, Sun L, Moul JW, HY W, McLeod DG, Amling C, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003;169(5):1670–5.
Yamamoto S, Yonese J, Kawakami S, Ohkubo Y, Tatokoro M, Komai Y, et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol. 2007;52(3):696–701.
Bertaglia V, Tucci M, Fiori C, Aroasio E, Poggio M, Buttigliero C, et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. Clin Genitourin Cancer. 2013;11(3):325–30. e1
Morote J, Orsola A, Planas J, Trilla E, Raventos CX, Cecchini L, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol. 2007;178(4 Pt 1):1290–5.
Tombal B. The importance of testosterone control in prostate cancer. Eur Urol Suppl. 2007;6(15):834–9.
van der Sluis TM, Bui HN, Meuleman EJ, Heijboer AC, Hartman JF, van Adrichem N, et al. Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. J Urol. 2012;187(5):1601–6.
Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int. 2010;105(5):648–51.
Yasuda Y, Fujii Y, Yuasa T, Yamamoto S, Yonese J, Fukui I. Do testosterone levels have prognostic significance in patients with metastatic prostate cancer treated with combined androgen blockade? Int J Urol. 2015;22(1):132–3.
Kamada S, Sakamoto S, Ando K, Muroi A, Fuse M, Kawamura K, et al. Nadir testosterone after long-term follow-up predicts prognosis of prostate cancer patients treated with combined androgen blockade. J Urol. 2015;193(4):E1086-E.
Klotz L, O’Callaghan C, Ding K, Toren P, Dearnaley D, Higano CS. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT (vol 33, pg 1151, 2015). J Clin Oncol. 2016;34(16):1965.
Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531–8.
Klotz L, Miller K, Crawford ED, Shore N, Tombal B, Karup C, et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol. 2014;66(6):1101–8.
Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447–54.
Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008;68(15):6407–15.
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352–60.
James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338–51.
Qu F, Xie W, Nakabayashi M, Zhang H, Jeong SH, Wang X, et al. Association of AR-V7 and prostate-specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer. Clin Cancer Res. 2017;23(3):726–34.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Sakamoto, S. (2018). Prognostic Significance of Monitoring Serum Testosterone in Primary ADT for Prostate Cancer. In: Arai, Y., Ogawa, O. (eds) Hormone Therapy and Castration Resistance of Prostate Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-10-7013-6_9
Download citation
DOI: https://doi.org/10.1007/978-981-10-7013-6_9
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-7012-9
Online ISBN: 978-981-10-7013-6
eBook Packages: MedicineMedicine (R0)